Trials / Completed
CompletedNCT03958071
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
Characteristics of IPF Patients Initiating Nintedanib, Pirfenidone or no Antifibrotic Treatment in the US
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13,264 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib initiators |
| DRUG | Pirfenidone | Pirfenidone initiators |
| OTHER | Untreated Cohort | Untreated |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
- First posted
- 2019-05-21
- Last updated
- 2021-11-15
- Results posted
- 2020-12-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03958071. Inclusion in this directory is not an endorsement.